Literature DB >> 26004777

Comparative Proteomics of Ovarian Cancer Aggregate Formation Reveals an Increased Expression of Calcium-activated Chloride Channel Regulator 1 (CLCA1).

Natasha Musrap1, Alessandra Tuccitto1, George S Karagiannis1, Punit Saraon1, Ihor Batruch2, Eleftherios P Diamandis3.   

Abstract

Ovarian cancer is a lethal gynecological disease that is characterized by peritoneal metastasis and increased resistance to conventional chemotherapies. This increased resistance and the ability to spread is often attributed to the formation of multicellular aggregates or spheroids in the peritoneal cavity, which seed abdominal surfaces and organs. Given that the presence of metastatic implants is a predictor of poor survival, a better understanding of how spheroids form is critical to improving patient outcome, and may result in the identification of novel therapeutic targets. Thus, we attempted to gain insight into the proteomic changes that occur during anchorage-independent cancer cell aggregation. As such, an ovarian cancer cell line, OV-90, was cultured in adherent and non-adherent conditions using stable isotope labeling with amino acids in cell culture (SILAC). Anchorage-dependent cells (OV-90AD) were grown in tissue culture flasks, whereas anchorage-independent cells (OV-90AI) were grown in suspension using the hanging-drop method. Cellular proteins from both conditions were then identified using LC-MS/MS, which resulted in the quantification of 1533 proteins. Of these, 13 and 6 proteins were up-regulated and down-regulated, respectively, in aggregate-forming cells compared with cells grown as monolayers. Relative gene expression and protein expression of candidates were examined in other cell line models of aggregate formation (TOV-112D and ES-2), which revealed an increased expression of calcium-activated chloride channel regulator 1 (CLCA1). Moreover, inhibitor and siRNA transfection studies demonstrated an apparent effect of CLCA1 on cancer cell aggregation. Further elucidation of the role of CLCA1 in the pathogenesis of ovarian cancer is warranted.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  CLCA1; aggregation; mass spectrometry (MS); metastasis; multicellular aggregates; ovarian cancer; proteomics; spheroids

Mesh:

Substances:

Year:  2015        PMID: 26004777      PMCID: PMC4498061          DOI: 10.1074/jbc.M115.639773

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  P-cadherin promotes ovarian cancer dissemination through tumor cell aggregation and tumor-peritoneum interactions.

Authors:  Akihiro Usui; Song Yi Ko; Nicolas Barengo; Honami Naora
Journal:  Mol Cancer Res       Date:  2014-01-21       Impact factor: 5.852

3.  Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids.

Authors:  R C Casey; K M Burleson; K M Skubitz; S E Pambuccian; T R Oegema; L E Ruff; A P Skubitz
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

4.  Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca2+-activated Cl- channel proteins.

Authors:  A D Gruber; R C Elble; H L Ji; K D Schreur; C M Fuller; B U Pauli
Journal:  Genomics       Date:  1998-12-01       Impact factor: 5.736

5.  A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro.

Authors:  Janet Myungjin Lee; Paulette Mhawech-Fauceglia; Nathan Lee; Lucineh Cristina Parsanian; Yvonne Gail Lin; Simon Andrew Gayther; Kate Lawrenson
Journal:  Lab Invest       Date:  2013-03-04       Impact factor: 5.662

6.  Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents.

Authors:  Giulio Francia; Shan Man; Beverly Teicher; Luigi Grasso; Robert S Kerbel
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 7.  Multicellular spheroids in ovarian cancer metastases: Biology and pathology.

Authors:  Kristy Shield; M Leigh Ackland; Nuzhat Ahmed; Gregory E Rice
Journal:  Gynecol Oncol       Date:  2009-01-10       Impact factor: 5.482

8.  Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype.

Authors:  Katharine L Sodek; Maurice J Ringuette; Theodore J Brown
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

9.  The transition from proliferation to differentiation in colorectal cancer is regulated by the calcium activated chloride channel A1.

Authors:  Bo Yang; Lin Cao; Bin Liu; Colin D McCaig; Jin Pu
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

10.  Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis.

Authors:  Kristy Shield; Clyde Riley; Michael A Quinn; Gregory E Rice; Margaret L Ackland; Nuzhat Ahmed
Journal:  J Carcinog       Date:  2007-06-14
View more
  12 in total

1.  Identification of Hub Genes in Colorectal Adenocarcinoma by Integrated Bioinformatics.

Authors:  Yang Liu; Lanlan Chen; Xiangbo Meng; Shujun Ye; Lianjun Ma
Journal:  Front Cell Dev Biol       Date:  2022-05-27

2.  Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy.

Authors:  Monika Englert-Golon; Bartosz Burchardt; Bartlomiej Budny; Szymon Dębicki; Blanka Majchrzycka; Elzbieta Wrotkowska; Piotr Jasiński; Katarzyna Ziemnicka; Radosław Słopień; Marek Ruchała; Stefan Sajdak
Journal:  Oncol Lett       Date:  2017-07-17       Impact factor: 2.967

3.  An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors.

Authors:  Qing Kay Li; Punit Shah; Yuan Tian; Yingwei Hu; Richard B S Roden; Hui Zhang; Daniel W Chan
Journal:  Clin Proteomics       Date:  2017-05-10       Impact factor: 3.988

4.  Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.

Authors:  Hong Qu; Yuling Chen; Guangming Cao; Chongdong Liu; Jiatong Xu; Haiteng Deng; Zhenyu Zhang
Journal:  Oncotarget       Date:  2016-12-13

Review 5.  Mass spectrometry-based proteomics techniques and their application in ovarian cancer research.

Authors:  Agata Swiatly; Szymon Plewa; Jan Matysiak; Zenon J Kokot
Journal:  J Ovarian Res       Date:  2018-10-01       Impact factor: 4.234

6.  High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy.

Authors:  Tzu-Ju Chen; Hong-Lin He; Yow-Ling Shiue; Ching-Chieh Yang; Li-Ching Lin; Yu-Feng Tian; Shang-Hung Chen
Journal:  Int J Med Sci       Date:  2018-07-30       Impact factor: 3.738

Review 7.  Emerging roles for multifunctional ion channel auxiliary subunits in cancer.

Authors:  Alexander S Haworth; William J Brackenbury
Journal:  Cell Calcium       Date:  2019-04-25       Impact factor: 6.817

8.  Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.

Authors:  Laura R Hardy; Melissa R Pergande; Karina Esparza; Kimberly N Heath; Hayat Önyüksel; Stephanie M Cologna; Joanna E Burdette
Journal:  Oncogene       Date:  2019-07-11       Impact factor: 9.867

9.  Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures.

Authors:  Simonas Daunys; Daumantas Matulis; Vilma Petrikaitė
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

10.  Quantitative analysis of gene expression in fixed colorectal carcinoma samples as a method for biomarker validation.

Authors:  Beata Ostasiewicz; Paweł Ostasiewicz; Kamila Duś-Szachniewicz; Katarzyna Ostasiewicz; Piotr Ziółkowski
Journal:  Mol Med Rep       Date:  2016-04-27       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.